Member Info for Dave_Ena_Merkel

..descending wedge on daily, very worst that could happen is a final flush to 825/830 if so it’ll be brisk if silver and gold keep moving up overnight (I’m bullish on both and both starting from nice, higher base, looking for future all time highs) - with the gap left from today too it’s gotta be a strong buy anywhere around here cos everything is pointing to a reversal especially if there’s a silver spike over weekend. If not, well it’ll be worth the wait. Similar reversal patterns on other miners - random pick ANG chart very similar.

Fres https://www.screencast.com/t/GX5GK7ILi
ANG https://www.screencast.com/t/iCPJHESmg

Godspeed!

....back to the top of the ride..
https://youtu.be/vWW2SzoAXMo

https://www.diaceutics.com/
multi million dollar partnership with BioReference laboratories
https://www.businesswire.com/news/home/20170424005689/en/Diaceutics-Signs-Multi-Million-Dollar-Partnership-BioReference-Laboratories-Improve

Through its partnership with BioReference, which works with 30,000 healthcare providers across the US, Diaceutics will have access to data from 50,000 patient samples per day. Coupled with insights from BioReference, the real-time data will help improve patient testing by ensuring that pharmaceutical companies better understand the testing patterns of physicians considering precision medicine therapies for patients.

In response to the COVID-19 global pandemic, BioReference has completed the following to help support patients, providers and government agencies:
Launched nationwide availability of a Real-Time Reverse Transcription Polymerase Chain Reaction (Real-Time RT-PCR) assay to aid healthcare providers in quickly and efficiently diagnosing patients.
Increased laboratory testing capacity to ensure patients and providers have greater access to testing – currently can accommodate in excess of 20,000 COVID-19 tests per day.
Collaborated with the New York State Department of Health and Governor Andrew M. Cuomo to provide testing for the first public drive-through testing facility on the East Coast, located in New Rochelle, NY, the epicenter for the New York State outbreak. Additional satellite testing sites to be set-up in the coming weeks. Read the Governor’s Office statement here.
Collaborated with the New York City Health and Hospital Corporation (NYC Health + Hospitals) to provide coronavirus disease 2019 (COVID-19) testing to patients within the more than 70 care locations across the city’s five boroughs.
Collaborated with the State of New Jersey to provide COVID-19 testing across the state, including access at the first five NJ drive-through testing facilities in the counties of Burlington, Essex, Hudson, Ocean and Union. Read the press release here.
Collaborated with the City of Detroit to provide COVID-19 testing at drive-through locations for residents by appointment.
Collaborated with the City of Miami to provide COVID-19 testing for Miami residents by appointment, and collaborated with Larkin Community Hospital to offer drive-through testing centers in South Florida, Hialeah and Hollywood, FL.
Announced continued prioritization of COVID-19 testing for hospital inpatients and critically ill patients around the country, with almost 200,000 patients tested to date.
More: https://www.bioreference.com/coronavirus

multi million dollar partnership with BioReference laboratories?

https://www.businesswire.com/news/home/20170424005689/en/Diaceutics-Signs-Multi-Million-Dollar-Partnership-BioReference-Laboratories-Improve

Through its partnership with BioReference, which works with 30,000 healthcare providers across the US, Diaceutics will have access to data from 50,000 patient samples per day. Coupled with insights from BioReference, the real-time data will help improve patient testing by ensuring that pharmaceutical companies better understand the testing patterns of physicians considering precision medicine therapies for patients.

In response to the COVID-19 global pandemic, BioReference has completed the following to help support patients, providers and government agencies:
Launched nationwide availability of a Real-Time Reverse Transcription Polymerase Chain Reaction (Real-Time RT-PCR) assay to aid healthcare providers in quickly and efficiently diagnosing patients.
Increased laboratory testing capacity to ensure patients and providers have greater access to testing – currently can accommodate in excess of 20,000 COVID-19 tests per day.
Collaborated with the New York State Department of Health and Governor Andrew M. Cuomo to provide testing for the first public drive-through testing facility on the East Coast, located in New Rochelle, NY, the epicenter for the New York State outbreak. Additional satellite testing sites to be set-up in the coming weeks. Read the Governor’s Office statement here.
Collaborated with the New York City Health and Hospital Corporation (NYC Health + Hospitals) to provide coronavirus disease 2019 (COVID-19) testing to patients within the more than 70 care locations across the city’s five boroughs.
Collaborated with the State of New Jersey to provide COVID-19 testing across the state, including access at the first five NJ drive-through testing facilities in the counties of Burlington, Essex, Hudson, Ocean and Union. Read the press release here.
Collaborated with the City of Detroit to provide COVID-19 testing at drive-through locations for residents by appointment.
Collaborated with the City of Miami to provide COVID-19 testing for Miami residents by appointment, and collaborated with Larkin Community Hospital to offer drive-through testing centers in South Florida, Hialeah and Hollywood, FL.
Announced continued prioritization of COVID-19 testing for hospital inpatients and critically ill patients around the country, with almost 200,000 patients tested to date.
More: https://www.bioreference.com/coronavirus

https://www.medgadget.com/2020/04/surge-in-demand-for-personalized-medicine-to-ensure-precision-medicine-market-global-market-to-register-usd-126-14-billion-by-2025.html

http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/PMC_Resources_on_COVID-192.pdf

Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.

https://www.diaceutics.com/covid19-oncology-impact-tracker/

https://www.independent.ie/business/irish/diaceutics-data-could-aid-efforts-to-treat-covid-19-39050525.html

https://www.irishtimes.com/business/health-pharma/diaceutics-sees-revenue-and-profit-rise-in-2019-1.4203990

https://youtu.be/3Y71iDvCYXA

Anyone looking at diaceutics?

Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.

https://www.diaceutics.com/covid19-oncology-impact-tracker/

Back in ftse 100 in March. Already eligible.

820p is coming carve - 1.61% fib extension target. Give it a week or so....

https://youtu.be/_epXwsJeXq0

Too fast to trade but a clue to where it’s going. Buy the dips - strong reversal pattern and uptrend well and truly intact. If it fills gap - buy, buy, buy.

https://www.tradingview.com/x/O8YoTlRe/

With detailed engineering almost complete, major equipment purchases completed, and a number of significant construction contracts awarded or under review, the JV Partners are also updating the capex required for the project. The pre-operative capital cost of US$395 million, from 1st January 2018, has been revised to $440 million (which is within the expected range of variance as engineering was advanced) to reflect additional actual expenditure incurred by the JV Partners on the underground project more recently, and bringing forward the full construction costs for two large life of mine ventilation shafts, plus some sustaining capital to facilitate the early underground start.



Octavio Alvídrez, Chief Executive Officer of Fresnillo plc, said:

"Juanicipio is an outstanding project which will generate strong returns for our shareholders, and significant benefits to the region. We continue to de-risk and refine the best construction plan that will drive the most value and ensure we capitalise on the opportunity that Juanicipio presents. I am pleased to confirm we are accelerating development of the underground mine and as a result, I expect the mine will be producing silver and gold ahead of schedule in 2020."

George Paspalas, Chief Executive Officer of MAG Silver, said:

"We are very excited about the decision to bring forward the underground mine development of the Juanicipio project. Producing quantities of saleable mineralisation provides a very beneficial de-risking opportunity that gives confidence to both partners that the originally envisioned plant production ramp up may be improved."

Juanicipio Project Highlights



· Fresnillo plc is the operator of Juanicipio and holds a 56% majority stake in the Joint Venture, with partner MAG Silver Corp. owning the remaining 44%.

· Total average annual anticipated production of 11.7 moz silver, 43.5 koz gold, with an initial life of mine (based on Indicated Resources only) of 12 years.

· Additional years of production expected to be supported by the current Inferred Resources, which are being converted into the Indicated category. Further exploration opportunities exist in the JV license area with potential to scale-up operations in the future.

· Juanicipio development expected to create approximately 2,750 jobs during construction and 1,720 jobs once at full production.

The information contained within this announcement is deemed by Fresnillo plc to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain. The person making the notification is Carlos Ortiz Mena, Head of Legal, Fresnillo plc. The time of the notification is 7:00 am UK time.
https://www.lse.co.uk/rns/FRES/statement-re-juanicipio-project-update-x6jdawdxhvc47j4.html

Juanicipio Project Status Update



· Underground mine will commence production ahead of schedule in mid-2020, realising commercial and operational de-risking opportunities for the joint venture.

· Over 25 km of underground development has been completed to date on the project.

· Based on detailed engineering, actual equipment purchases and construction contracts, pre-operative capex, from 1st January 2018, has increased by 11.4% from US$395 million to US$440 million also reflecting expenditure incurred on underground development, supporting infrastructure, and bringing forward some sustaining capital to facilitate the early underground start.

· Mineralised material from development and initial production stopes to be processed at the Fresnillo beneficiation plant from June 2020 pending completion of the Juanicipio plant.

· Juanicipio now expected to reach 85% name plate capacity in Q4 2021 (previous guidance 65%) and 90-95% in 2022 (in line with previous guidance). Commissioning of the flotation plant will be underway mid-2021.

· Access to the upper portion of the resource has been achieved. Initial development indicates that the grade and width of the vein is in line with previous estimates.

· Exploration is ongoing on the property with the intention to increase the deeper resources and targeting new veins.



Project Benefits



By bringing forward the start-up of the underground mine to June 2020, the JV Partners are securing a number of positive outcomes for the project:



· Improved cash flow by deferring capex spend and accelerating income from the new production ahead of plan.

· De-risking the metallurgical process allowing a quicker and more certain ramp-up to 4,000 tonnes per day.

· Increased certainty around the geological block model prior to start-up of flotation plant.



Mine development continues to advance, reaching over 25 km by the end of January 2020. Development activities will continue in the next few months and we anticipate the first stope being fully prepared by 3Q20.



The schedule for the construction of the flotation plant has been adjusted to enable the most efficient use of contractor labour, and commissioning is now anticipated by mid-2021 (previous guidance was construction completion by the end of 2020 with commissioning early 2021).



In the interim, mineralised material from development and initial production stopes will be processed at the Fresnillo beneficiation plant from June 2020. The Fresnillo plant is expected to have spare capacity as the mine continues its operational recovery.

None of this will matter. Silver and Gold prices change everything - 800p is coming to say boo to you! Rrright at the top of the channel. The Smart money/ shorts closed out November last year, check the volume spike. Check the disclosures.... Look what has been happening with price action and volume recently...

A lua prateada se escondeu
E o sol dourado apareceu
Amanheceu um lindo dia
Cheirando alegria

The silver moon hid
And the golden sun appeared
It dawned a beautiful day
Smelling joy

https://youtu.be/YSA08dQqCNk

Good Luck

El Mañana...

https://youtu.be/hji4gBuOvIQ

Note - it’s in a rising wedge so if it doesn’t take out Jan high next week, chances are it’ll fall out of wedge and deffo get a better buy in. It’ll be clear mid week, next week I reckon.

I said this last week carve - signals liquidity hunting to me. This is gonna make a nice weekly close, big volume in today too, question is, is wether it’s a sell off double top or positioning for breakout? The closing price today will hopefully give a clue.